References

COVID-19 cases and hospitalizations by COVID-19 vaccination status and previous COVID-19 diagnosis—California and New York, May-November 2021

10.15585/mmwr.mm7104e1 · 2022 · External reference

Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine

10.1056/nejmoa2034577 · 2020 · External reference

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

10.1016/s0140-6736(20)32661-1 · 2021 · External reference

Waning antibody responses in COVID-19: what can we learn from the analysis of other coronaviruses?

10.1007/s15010-021-01664-z · 2022 · External reference

Comparison of antibody response elicited by ChAdOx1 and BNT162b2 COVID-19 vaccine

10.3346/jkms.2021.36.e311 · 2021 · External reference

SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses

10.1016/j.cell.2021.12.046 · 2022 · External reference

Adaptive immune determinants of viral clearance and protection in mouse models of SARS-CoV-2

10.1126/sciimmunol.abl4509 · 2021 · External reference

Correlates of protection against SARS-CoV-2 in rhesus macaques

10.1038/s41586-020-03041-6 · 2021 · External reference

Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity

10.1016/j.cell.2020.09.038 · 2020 · External reference

Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19

10.1016/j.cell.2020.08.017 · 2020 · External reference

Two X-linked agammaglobulinemia patients develop pneumonia as COVID-19 manifestation but recover

10.1111/pai.13263 · 2020 · External reference

Anti-CD20 and COVID-19 in multiple sclerosis and related disorders: a case series of 60 patients from Madrid, Spain

10.1016/j.msard.2020.102185 · 2020 · External reference

COVID-19 in a MS patient treated with ocrelizumab: does immunosuppression have a protective role?

10.1016/j.msard.2020.102120 · 2020 · External reference

Divergent SARS CoV-2 Omicron-reactive T- and B cell responses in COVID-19 vaccine recipients

10.1126/sciimmunol.abo2202 · 2022 · External reference

SARS-CoV-2–reactive T cells in healthy donors and patients with COVID-19

10.1038/s41586-020-2598-9 · 2020 · External reference

T follicular helper cell biology: a decade of discovery and diseases

10.1016/j.immuni.2019.04.011 · 2019 · External reference

The other function: class II–restricted antigen presentation by B cells

10.3389/fimmu.2017.00319 · 2017 · External reference

Coronavirus disease 2019 in patients with inborn errors of immunity: an international study

10.1016/j.jaci.2020.09.010 · 2021 · External reference

COVID-19 in patients with primary and secondary immunodeficiency: the United Kingdom experience

10.1016/j.jaci.2020.12.620 · 2021 · External reference

Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial

10.1016/j.ebiom.2021.103705 · 2021 · External reference

SARS-CoV-2 vaccine responses in individuals with antibody deficiency: findings from the COV-AD study

10.1007/s10875-022-01231-7 · 2022 · External reference

Paucity and discordance of neutralising antibody responses to SARS-CoV-2 VOCs in vaccinated immunodeficient patients and health-care workers in the UK

10.1016/s2666-5247(21)00157-9 · 2021 · External reference

Analysis of serological biomarkers of SARS-CoV-2 infection in convalescent samples from severe, moderate and mild COVID-19 cases

10.3389/fimmu.2021.748291 · 2021 · External reference

Pseudotype neutralization assays: from laboratory bench to data analysis

10.3390/mps1010008 · 2018 · External reference

Unresolved reference

External reference

Imaging and clinical features of patients with 2019 novel coronavirus SARS-CoV-2

10.1007/s00259-020-04735-9 · 2020 · External reference

mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern

10.1126/science.abm0829 · 2021 · External reference

An autologous dendritic cell vaccine promotes anticancer immunity in patients with ovarian cancer with low mutational burden and cold tumors

10.1158/1078-0432.ccr-21-4413 · 2022 · External reference

IgG subclasses and allotypes: from structure to effector functions

10.3389/fimmu.2014.00520 · 2014 · External reference

IgA deficiency

2022 · External reference

Comparison of IgG and neutralizing antibody responses after one or two doses of COVID-19 mRNA vaccine in previously infected and uninfected individuals

10.1016/j.eclinm.2021.101018 · 2021 · External reference

Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations

10.1016/j.immuni.2021.07.008 · 2021 · External reference

Multiple HIV-1–specific IgG3 responses decline during acute HIV-1: implications for detection of incident HIV infection

10.1097/qad.0b013e32834b348e · 2011 · External reference

Competition for FcRn-mediated transport gives rise to short half-life of human IgG3 and offers therapeutic potential

10.1038/ncomms1608 · 2011 · External reference

Humoral and T-cell responses to SARS-CoV-2 vaccination in patients receiving immunosuppression

10.1136/annrheumdis-2021-220626 · 2021 · External reference

COVID-19 vaccine–induced T-cell responses in patients with rheumatoid arthritis: preferential induction by ChAdOx1

10.1016/s2665-9913(22)00027-3 · 2022 · External reference

Differential immunogenicity of BNT162b2 or ChAdOx1 vaccines after extended-interval homologous dual vaccination in older people

10.1186/s12979-021-00246-9 · 2021 · External reference

Immunogenicity of single vaccination with BNT162b2 or ChAdOx1 nCoV-19 at 5-6 weeks post vaccine in participants aged 80 years or older: an exploratory analysis

10.1016/s2666-7568(21)00169-0 · 2021 · External reference

Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses

10.1038/s41591-020-01179-4 · 2021 · External reference

The activation of bystander CD8+ T cells and their roles in viral infection

2019 · External reference

Impaired cytotoxic CD8+ T cell response in elderly COVID-19 patients

2020 · External reference

Homologous and heterologous COVID-19 booster vaccinations

10.1056/nejmoa2116414 · 2022 · External reference

COVID-19 vaccines mix-and-match: the concept, the efficacy and the doubts

10.1002/jmv.27463 · 2022 · External reference